This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Fluid/drug administration in paediatric ALS

Authoring team

The preferred route for administering fluids and drugs is via a peripheral intravenous line enabling prolonged infusion and high flow rates. In children however, peripheral access may be difficult, and although central access may be attempted this is often difficult and hazardous especially in the very young. An effective, rapidly obtained alternative to peripheral venous access is the intraosseus route. It is recommended for children up to the age of six years. Fluids and drugs may be infused rapidly, and samples of marrow may be obtained for routine investigations such as glucose, urea and electrolytes and full blood count. The intraosseous route however should not be used for long term access and should be replaced with an intravenous cannula when appropriate.

If neither intravenous or intraosseous access can be obtained then certain drugs such as lignocaine, epinephrine, atropine and naloxone (LEAN drugs) may be administered via the endotracheal tube. Ten times the usual dose should be used and injected deep into the bronchial tree, with a fine bore cannula, then flushed with an equal volume of saline.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.